NEOVACS
-
EUR
(-)
- 15 min delayed data - Euronext Paris
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | ALNEV |
| ISIN: | FR001400TG47 |
NEOVACS news, videos and press releases
For more news please use our advanced search feature.
NEOVACS - More news...
NEOVACS - More news...
- 12/28/2022 - 14:20 Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development
- 05/19/2020 - 15:30 NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020
- 05/18/2020 - 05:00 VALIDATION OF THE "RESTARTED" PLAN BY THE PARIS COMMERCIAL COURT
- 05/04/2020 - 16:30 DRAFT CONTINUITY PLAN // REVIEW HEARING SCHEDULED FOR MAY 6th, 2020
- 03/09/2020 - 17:30 EXTENSION OF THE OBSERVATION PERIOD IN THE FRAME OF REOGANIZATION PROCEEDINGS AND UPDATE ON RandD PROGRAMS
- 12/06/2019 - 16:45 OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS
- 10/02/2019 - 19:31 NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS
- 09/30/2019 - 06:30 NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER
- 09/09/2019 - 15:45 Neovacs : 2019 Financial Calendar
- 07/09/2019 - 05:30 NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT
- 06/27/2019 - 05:30 NEOVACS ANNOUNCES THE APPOINTMENT of Dr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR
- 06/05/2019 - 05:30 Neovacs to present the pre-clinical results of its IFNalpha Kinoid to treat type 1 diabetes - American Diabetes Association's 79th scientific sessions
- 05/16/2019 - 05:30 Neovacs to present the pre-clinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid to treat allergic Asthma
- 03/25/2019 - 06:30 Neovacs reports full-year 2018 Financial results and provides corporate update
- 02/19/2019 - 12:30 Néovacs : Agenda financier 2019
- 02/05/2019 - 01:30 Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris
- 01/24/2019 - 11:45 Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress
- 01/08/2019 - 06:30 NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT
- 12/11/2018 - 06:30 Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid
- 11/20/2018 - 16:45 Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies
- 11/07/2018 - 16:45 Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma
- 10/30/2018 - 16:50 NEOVACS : HALF-YEAR 2018 FINANCIAL RESULTS
- 10/11/2018 - 05:00 NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFNalpha KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG (CKD) PHARMACEUTICALS
- 09/11/2018 - 05:00 NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA
- 07/03/2018 - 05:00 NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS
- 05/15/2018 - 16:05 NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE AND JAPAN
- 03/30/2018 - 05:30 NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017 FINANCIAL RESULTS
- 02/22/2018 - 06:00 NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA
- 02/16/2018 - 17:00 NEOVACS :2018 Financial Calendar
- 02/13/2018 - 06:00 Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus
